NCT00472953 (iINHALE 8) is a Phase 3 clinical trial of inhaled human insulin in Diabetes, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT00472953?

NCT00472953 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT00472953?

Interventions in NCT00472953: inhaled human insulin, insulin aspart.

What condition does NCT00472953 study?

NCT00472953 studies Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Chronic Obstructive Pulmonary Disease.

Is NCT00472953 still recruiting?

NCT00472953 is currently terminated. Last updated 1 March 2017.

Last reviewed 2017-03-01 · How we verify

NCT00472953: iINHALE 8

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)

Terminated Phase 3 Last updated 1 March 2017

What this trial tests

Phase 3 trial testing inhaled human insulin in Diabetes in 38 participants. Terminated before completion.

Timeline

15 May 2007

Primary endpoint
5 March 2008

5 March 2008

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	15 May 2007
Primary completion	5 March 2008
Estimated completion	5 March 2008
Sites	27 locations across Slovakia, Taiwan, Argentina, Romania, Thailand, Turkey (Türkiye), India

Drugs / interventions tested

inhaled human insulin — full drug profile →
insulin aspart (INSULIN ASPART) — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →
Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

30 and older, any sex, with Diabetes or Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in Europe, Asia and South America. A one-year clinical trial to compare the safety of inhaled human insulin to subcutaneous insulin aspart in subjects with type 1 or type 2 diabetes and chronic obstructive pulmonary disease (COPD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of inhaled human insulin

Trials testing the same drug.

NCT03307512 — PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD · Phase 2 · terminated
NCT00523042 — Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma · Phase 3 · terminated
NCT00469586 — Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes · Phase 3 · terminated
NCT00427154 — Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes · Phase 3 · terminated
NCT00411892 — Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes · Phase 3 · terminated

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00472953 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 1 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00472953.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing